Hot Pursuit     11-Jun-24
Biocon Ltd soars 2.25%, up for fifth straight session
Biocon Ltd is quoting at Rs 347.55, up 2.25% on the day as on 12:44 IST on the NSE. The stock is up 45.36% in last one year as compared to a 25.46% spurt in NIFTY and a 54.03% spurt in the Nifty Pharma.

Biocon Ltd gained for a fifth straight session today. The stock is quoting at Rs 347.55, up 2.25% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.34% on the day, quoting at 23337.55. The Sensex is at 76691.49, up 0.26%. Biocon Ltd has risen around 15.22% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 4.56% in last one month and is currently quoting at 19774.7, up 0.14% on the day. The volume in the stock stood at 50.37 lakh shares today, compared to the daily average of 103.49 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 348.05, up 2.1% on the day. Biocon Ltd is up 45.36% in last one year as compared to a 25.46% spurt in NIFTY and a 54.03% spurt in the Nifty Pharma index.

The PE of the stock is 377.5 based on TTM earnings ending March 24.

Previous News
  Biocon
 ( Results - Analysis 09-May-25   10:36 )
  Biocon to hold AGM
 ( Corporate News - 09-May-25   09:23 )
  Board of Biocon recommends final dividend
 ( Corporate News - 09-May-25   09:23 )
  Biocon consolidated net profit rises 154.24% in the March 2025 quarter
 ( Results - Announcements 09-May-25   07:38 )
  Biocon edges higher after biologics arm secures multiple market access deals for Yesintek
 ( Hot Pursuit - 05-May-25   09:31 )
  Biocon’s board OKs to raise Rs 4,500-cr
 ( Hot Pursuit - 24-Apr-25   08:11 )
  Board of Biocon approves fund raising up to Rs 4,500 cr
 ( Corporate News - 23-Apr-25   20:05 )
  Biocon to consider fund Raising
 ( Corporate News - 21-Apr-25   09:37 )
  Biocon surges on U.S. deal for Eylea copycat drug
 ( Hot Pursuit - 15-Apr-25   09:58 )
  Biocon Biologics inks a settlement and license agreement with Regeneron
 ( Corporate News - 15-Apr-25   09:29 )
  Biocon Biologics receives USFDA approval for Jobevne™ (Biosimilar Bevacizumab)
 ( Corporate News - 10-Apr-25   13:25 )
Other Stories
  Hero Motocorp gains after Q4 PAT climbs 6% YoY to Rs 1,081 cr
  13-May-25   15:49
  Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%
  13-May-25   15:17
  Tata Steel Q4 PAT zooms 113% YoY to Rs 1,301 cr
  13-May-25   15:02
  Aether Industries Ltd leads losers in 'A' group
  13-May-25   15:00
  Ambica Agarbathies Aroma & Industries Ltd leads losers in 'B' group
  13-May-25   14:45
  IIFL Finance climbs as foreign broker upgrades to 'buy'
  13-May-25   14:41
  TD Power Systems jumps after Q4 PAT climbs 83% YoY to Rs 53 cr
  13-May-25   14:40
  Volumes soar at JM Financial Ltd counter
  13-May-25   14:30
  Patel Engg slides after Q4 PAT drops 73% YoY to Rs 33 cr
  13-May-25   14:28
  Information Technology stocks slide
  13-May-25   14:00
Back Top